$iShares Silver Trust(SLV)$ For silver, 100 is just a midpoint, not the destination. In this kind of market, the biggest mistake isn’t getting the direction wrong — it’s selling too early Once you sell and prices move higher, buying back becomes psychologically hard, and that’s how most people miss long-term trends. With SLV, I’m holding tight and letting the trend play out.
$Palantir Technologies Inc.(PLTR)$ ’s government and AI contracts keep rolling in—locked in a small gain. My first trade qualified for Contra 688, and the SGD688 voucher arrived instantly. Software monetization is accelerating; the long-term story is just beginning.
$Canaan Inc.(CAN)$ The shareholding structure has solidified, and the trend is clear! The long-term bull market setup is firmly in place, likely following a pattern of "long rallies, short dips." Hold tight—expecting further gains ahead!
$Alphabet(GOOG)$ surged on strong earnings! Today’s pullback is natural—key is holding the gap. With AI and search still strong, the uptrend may continue!
$SUPER MICRO COMPUTER INC(SMCI)$ Finally waited for this market trend—patience truly is the key to investing! As a core player in the AI server sector, its importance to computing infrastructure is undeniable. Despite some volatility along the way, the long-term trend remains solid, and I’m still confident in its growth potential. For a company driven by both technology and real-world applications, holding steady is the only way to see the future.
$U.S. Steel(X)$ The deal is official! Last Friday, Trump signed an executive order approving Nippon Steel’s $14.9B full acquisition of U.S. Steel，on the condition that both companies sign a national security agreement with the U.S. Treasury. This isn’t just a buyout，it’s a transformation. With Japanese capital and operational discipline coming in, U.S. Steel could be headed into a whole new era. The merger might bring more synergies than the market is currently pricing in.
$Zai Lab Ltd(ZLAB)$ Big win for ZLAB，no doubt this is major news. Drug 1310 just scored orphan drug + fast track approval = 7 years of exclusivity and a faster launch path. That puts them ahead of $INNOVENT BIO(01801)$ and $HENGRUI PHARMA(01276)$ , who’ve already licensed out. Zai Lab’s still holding it tight… curious to see their next move. Could get interesting.
$Adobe(ADBE)$ Congratulations on reaching the 400 mark. SAAS（Software as a Service） has a good profit model. Hold on firmly and look forward to better returns!